Does isoniazid reduce side effects of intravesical bacillus Calmette- Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911

Journal of Urology

Volumn 157, Issue 4, 1997, Pages 1246-1249

  Vegt, Peter D J ^a   Van Der Meijden, Adrian P M ^a   Sylvester, Richard ^a   Brausi, Maurizio ^a   Höltl, Wolfgang ^a   De Balincourt, Christine ^a  

^a NONE

Author keywords

BCG vaccine; bladder neoplasms; carcinoma; isoniazid

Indexed keywords

BCG VACCINE; ISONIAZID;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTITIS; FEVER; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOBACTERIUM BOVIS; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATITIS; RASH; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0030936133     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64936-X     Document Type: Article

References (15)

1. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavity bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116: 180, 1976.
2. Martínez-Piñeiro, J. A., León, J. J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J., García Matres, M. J. and Cárcamo, P.: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
3. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. A. and Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 1991.
4. Debruyne, F. M. J., van der Meijden, A. P. M., Geboers, A. D. H., Franssen, M. P. H., van Leeuwen, M. J. W., Steerenberg, P. A., de Jong, W. H. and Ruitenberg, E. J.: BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of a randomized prospective trial. Urology, suppl., 31: 21, 1988.
5. Witjes, J. A., van der Meijden, A. P. M., Witjes, W. P., Doesburg, W., Schaafsma, H. E., Debruyne, F. M. J. and the members of the Dutch South-East Cooperative Urological Group: A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Eur. J. Cancer, suppl. 12, 29a: 1672, 1993.
6. Lamm, D. L., van der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A. and Debruyne, F. M. J.: Incidence and treatment of complications of bacillus calmette-guerin intravesical therapy in superficial bladder cancer. J. Urol., 147: 596, 1992.
7. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
8. Blumenstein, B. A., Lamm, D., Jewett, M. A. S., Humphries, G., Boux, L., Montie, J. E., Scardino, P. T., Grossman, H. B., Crawford, E. D., Smith, J. A. and Stanisic, T.: Effect of colony-forming unit dose of Connaught BCG on outcome to immunotherapy in superficial bladder cancer. A SWOG study. J. Urol., part 2, 143: 340A, abstract 608, 1990.
9. Martinez-Pineiro, J. A., Solsona, E., Flores, N. and Isorna, S.: Improving the safety of BCG immunotherapy by dose reduction. Eur. Urol., suppl. 1, 27: 13, 1995.
10. Guérin, C.: The history of BCG. In: BCG Vaccine: Tuberculosis-Cancer. Edited by S. R. Rosenthal. Littleton, Massachusetts: P. S. G. Publishing Company, Inc., p. 37, 1980.
11. Lamm, D. L., Steg, A., Boccon-Gibod, L., Morales, A., Hanna, M. G., Jr., Pagano, F., Alfthan, O., Brosman, S., Fisher, A. F., Jakse, G., Chisholm, G. D., van der Meijden, A. P. M. and Debryune, F. M. J.: Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: BCG in Superficial Bladder Cancer. Edited by F. M. J. Debruyne, L. Denis and A. P. M. van der Meijden. New York: Alan R. Liss, Inc., pp. 335-355, 1989.
12. Van der Meijden, A. P. M., van Klingeren, B., Steerenberg, P. A., De Boer, L. C., De Jong, W. H. and Debruyne, F. M. J.: The possible influence of antibiotics on results of bacillus Calmette-Guerin intravesical therapy for superficial bladder cancer. J. Urol., 146: 444, 1991.
13. De Boer, L. C., Steerenberg, P. A., van der Meijden, A. P. M., van Klingeren, B., de Jong, W. H., Elgersma, A., Debruyne, F. M. J. and Ruitenberg, E. J.: Impaired immune response by Isoniazid treatment during intravesical BCG administration in the guinea pig. J. Urol., 148: 1577, 1992.
14. Stassar, M. J., Vegt, P. D., Steerenberg, P. A., van der Meijden, A. P., Meiring, H. D., Dessens-Kroon, M., Geertzen, H. G. M. and den Otter, W.: Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol. Res., 22: 177, 1994.
15. Miller, B.: Preventive therapy for tuberculosis. Med. Clin. N. Amer., 77: 1263, 1993.